CRA CRA Adverse Event Reporting & Safety Monitoring 2 — Questions and Answers
Question 1: What is the purpose of causality assessment in adverse event reporting during a clinical trial?
- To determine the severity grade of the adverse event
- To assess whether the adverse event is related to the investigational product (Correct answer)
- To determine whether the subject should be withdrawn from the study
- To identify the genetic factors contributing to the adverse event
Correct answer: To assess whether the adverse event is related to the investigational product
Causality assessment determines the likelihood that an adverse event is related to the investigational product, which influences reporting obligations and safety decisions.
Question 2: Which of the following is NOT a standard causality category used by investigators when assessing whether an adverse event is related to study drug?
- Definitely related
- Probably related
- Unlikely related
- Inevitably related (Correct answer)
Correct answer: Inevitably related
Standard causality categories include definitely, probably, possibly, unlikely, and unrelated; 'inevitably related' is not a recognized causality classification.
Question 3: An investigator in a US clinical trial observes a new, unexpected serious adverse event that is possibly related to the study drug. To whom should this be reported first?
- The FDA directly via MedWatch
- The sponsor within the timeframe specified in the protocol (Correct answer)
- The IRB within 24 hours
- The Data Safety Monitoring Board at the next scheduled meeting
Correct answer: The sponsor within the timeframe specified in the protocol
Investigators must report SAEs to the sponsor within the timeframe specified in the protocol (typically 24–48 hours), and the sponsor then fulfills FDA reporting obligations.
Question 4: What is the primary difference between an Adverse Event (AE) and an Adverse Drug Reaction (ADR) in clinical research?
- An AE is always serious while an ADR can be non-serious
- An ADR has at least a reasonable causal relationship to the investigational product while an AE may not (Correct answer)
- An ADR is only applicable to approved drugs while an AE applies to investigational drugs
- An AE requires hospitalization while an ADR does not
Correct answer: An ADR has at least a reasonable causal relationship to the investigational product while an AE may not
An AE is any untoward event regardless of causality, while an ADR requires at least a reasonable possibility of a causal relationship with the investigational product.
Question 5: During an ongoing blinded clinical trial, a sponsor receives an unblinded SAE report suggesting a potential safety signal. What is the appropriate first action?
- Immediately unblind all participants and terminate the trial
- Assess the SAE without unblinding to preserve trial integrity, unless unblinding is clinically necessary (Correct answer)
- Report the signal to the FDA within 24 hours regardless of assessment
- Convene the full steering committee before taking any action
Correct answer: Assess the SAE without unblinding to preserve trial integrity, unless unblinding is clinically necessary
Sponsors should assess the SAE to determine if unblinding is necessary; unnecessary unblinding compromises trial integrity, so it should only occur when clinically required.
Question 6: Under 21 CFR 312.32(c)(1)(ii), within what timeframe must a sponsor submit an expedited IND safety report for an unexpected serious adverse drug reaction that is NOT fatal or life-threatening?
- 7 calendar days
- 10 calendar days
- 15 calendar days (Correct answer)
- 30 calendar days
Correct answer: 15 calendar days
Unexpected serious adverse drug reactions that are not fatal or life-threatening must be reported to the FDA within 15 calendar days of the sponsor receiving the information.
CRA CRA Adverse Event Reporting & Safety Monitoring 2
What is the purpose of causality assessment in adverse event reporting during a clinical trial?